Followers | 827 |
Posts | 32060 |
Boards Moderated | 7 |
Alias Born | 03/22/2016 |
Tuesday, November 02, 2021 5:33:13 AM
Recent ATHA News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/17/2024 01:00:08 PM
- Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases • GlobeNewswire Inc. • 09/17/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:50:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:49:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:48:21 PM
- Nvidia Subpoenaed by DOJ, Athira Pharma Shares Plunge 71% After Study Fails, Zscaler Falls 15% Post-Earnings • IH Market News • 09/04/2024 09:50:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 08:01:11 PM
- Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease • GlobeNewswire Inc. • 09/03/2024 08:01:00 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 08/09/2024 08:05:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:15:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:10:10 PM
- Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024 • GlobeNewswire Inc. • 07/31/2024 12:05:00 PM
- Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients • GlobeNewswire Inc. • 06/12/2024 11:00:00 AM
- Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) • GlobeNewswire Inc. • 06/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 08:05:10 PM
- Athira Pharma to Participate in Upcoming June Conferences • GlobeNewswire Inc. • 05/29/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 11:03:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 10:58:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 10:56:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 09:00:13 PM
- Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action • GlobeNewswire Inc. • 05/17/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:10:16 PM
- Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates • GlobeNewswire Inc. • 05/15/2024 08:05:00 PM
- Athira Pharma to Participate in Upcoming May Conferences • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM